Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC

In this study, patients with EGFR/ALK wild-type, resectable locally advanced NSCLC are expected to receive 1 cycle of chemoimmunotherapy as neoadjuvant therapy, followed by SBRT to the primary lung lesion, and chemoimmunotherapy for 2 cycles. Surgical treatment will be given within 4-6 weeks after the last cycle of chemoimmunotherapy, then immunotherapy maintenance for 1 year.

Trial Details

NCT ID
NCT06718309
Phase
PHASE2
Sponsor
First People's Hospital of Hangzhou
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Chemotherapy
  • Immunotherapy
  • Radical resection of lung cancer
  • SBRT
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Histologically or pathologically confirmed, newly diagnosed non-small cell lung cancer patients;
  • Age ≥18 years;
  • (Eastern Cooperative Oncology Group, ECOG) (Performance Status, PS) score 0-1;
  • According to the 8th-9th edition of (American Joint Committee on Cancer, AJCC) (stage II-IIIA, for stage IIIB included T3-4N2, T4 only included tum…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →